GEROPHARM NEW PARTNERING OPPORTUNITIES IN SAINT-PETERSBURG PHARMACEUTICAL CLUSTER

Similar documents
PHARMACEUTICAL MANUFACTURING AND DISTRIBUTION. The Headquarter company: business development strategies, sales and marketing

Grindeks years of growth

ISPE Annual Meeting 29 October 1 November 2017 San Diego, CA

AKRIKHIN: COMPANY PRESENTATION

Manufacturing of pharmaceutical products in Russia under full cycle conditions

The Future of Pharmaceuticals for Human Use in Europe Cefic Input to the Consultation Process: Deadline for Submission 12/10/2007 Date: 10/10/07

ORGANIZATION OF A SPECIALIZED PRODUCTION IN RUSSIA. INDUSTRIAL COOPERATION AND VENDOR MANAGEMENT

Development of contract manufacturing on the example PJSC «Pharmimex»

Biopeople at a Glance

Economic Growth through Research & Innovation: The Greek Pharma Case

CJSC Rafarma is a multi-purpose pharmaceutical integrated plant for production of all types of pharmaceutical forms of medicinal products of

INVESTMENT ON PHARMACEUTICALS: THE VIEW OF MINISTRY OF HEALTH

The pessimist sees difficulty in every opportunity, the optimist sees the opportunity in every difficulty. Churchill, Winston

Finding the right partner for preclinical into phase I. Facts, Threats & Opportunities

GEROPHARM Group. Pharmaceutical Manufacturing and Distribution. Innovative biotechnology. R&D Center

COMPANY PRESENTATION. Health is a treasure we share World Medicine World Medicine

BioWorld s PARTNER in FOCUS: Open Innovations: Moscow

NAPAK. Development of regional and international cluster cooperation. Establishment of auto-industrial clusters in Russia.

Yaroslavl Oblast Government. The Yaroslavl Oblast pharmaceutical industry and medical innovation cluster

IP, LOCAL MANUFACTURING, INDUSTRIAL AND ACCESS POLICIES

REIMAGINING DRUG DEVELOPMENT:

India Pharma Summit

2 nd WORLD GRAIN FORUM. 30 September 2 October, 2016 Sochi

Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (COM) COURSE DESCRIPTION

Korea GMP & DMF. April Korea Pharmaceutical Traders Association Deputy director Oh Hyun, Kwon

Qualified Persons (IMP) Don Wallace Regional QA Pharmacist 27 th May 2014

FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME INTEGRATED PRODUCTION PLATFORMS GMP-COMPLIANT PRODUCTION OF BIOPHARMACEUTICALS

We make drugs smarter

Investment offer. I Name of the project and company information:

Idea behind the project

Technology Transfer, Academic and Industry Cooperations

Science Technology Innovation system regarding the Thai Healthcare and Medical Industries

Your partner in the pharmaceutical industry

ENERGY SAVING AND EFFICIENCY PROJECTS IMPLEMENTED BY GAZPROM PROMGAZ IN COOPERATION WITH EUROPEAN PARTNERS

China Pharmaceutical Equipment Industry Report, Mar. 2013

Evonik Birmingham Laboratories

CONTRACTING CELL CULTURE

CASE STUDY JAPANESE VACCINES MANUFACTURER UNIGEN IMPLEMENTS PAS-X AT ONE OF THE LARGEST BIOTECH PLANTS IN ONLY FOUR MONTHS

CASE STUDY JAPANESE VACCINES MANUFACTURER UNIGEN IMPLEMENTS PAS-X AT ONE OF THE LARGEST BIOTECH PLANTS IN ONLY FOUR MONTHS

Guide to Scientific and Regulatory Advice for GXP activities

Health Canada Mutual Recognition Agreement (MRA) Programme

OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET

4. Pharmaceuticals Sector and Opportunity Ahead

COPING WITH INCREASING NEEDS FOR INSPECTIONS: ASEAN INITIATIVES. Abida Syed M Haq Ministry of Health, Malaysia

FY18 Results Presentation 12 months to 30 June 2018

Pharmaceutical Industries

State Control of Medicines and Medical Devices in Russian Federation

OFFICIAL SUPPORT. Apteka is held with an active support of the leading industry associations: Association of Russian Pharmaceutical Manufacturers

Novartis Business Services HR University Relations. Chemical and Analytical Development. Early Talent Program

Approval process for veterinary medicinal products in Japan

Your bridge to. better medicines

VTN your reliable and effective partner providing tailored logistics solutions

RUSSIAN SPECIAL ECONOMIC ZONES

BIOTECH IN FRANCE. key info in. points

ENTRANCE PHARMACEUTICALS & RESEARCH CENTER

Almac Overview.

Special Economic Zone of Technical and Innovative Type «Tomsk»

Key Definitions 6/16/2015

Materials Management Traceability, CEPs and managing non-conforming sites

CLINICAL RESEARCH? TAKE A LOOK AT MEXICO

Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs)

Natalia Nayanova Director of Clinical Operations and General Manager. Accell Clinical Research 2016

To meet the challenge of providing safe, cost-effective medicines for the world s largest

No. : 665/6927 Date : April 16, 2016 To : All pharmaceutical companies

Drug Registration in BRICS countries: Opportunities and Challenges. Judith ter Horst 1 November 2018

Indian Pharmaceutical Industry. January 2018

6. Vision 3: Leading the Japanese economy forward as a high value-added industry"

On behalf of the Cystic Fibrosis Foundation (CFF) and the 30,000 people with cystic

Why Culture Matters in Cancer Research

CONTRACT RESEARCH SERVICES

Survival Kit for Regulatory Inspections

IMPLEMENTATION OF THE EU FALSIFIED MEDICINES DIRECTIVE, 2011/62/EU. IPA/EDQM/WHO 2012, Mumbai

BULGARIAN PHARMACEUTICAL POLICY AND LEGISLATION IN THE CONTEXT OF THE EU ACCESSION

Pharmaceutical Good Manufacturing Practice. Contents are subject to change. For the latest updates visit

China Pharmaceutical Glass Packaging Industry Report, Jun. 2015

NIH-RAID: A ROADMAP Program

Investment potential of the Pskov Region

Speech by H.E. Eng. Tarek Kabil Minister of Trade and Industry

Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective

Jefferies 2018 Global Healthcare Conference. June 7, 2018

Strategic Overview of the Biotechnology Industry

The Biotechnology Industry in Taiwan

Int. J. Pharm. Sci. Rev. Res., 31(2), March April 2015; Article No. 04, Pages: A Review on Drug Approval in Regulated and Non-Regulated Markets

Embassy of Denmark in Vietnam 2 / 10

GUIDELINES FOR REGISTRATION OF IMPORTERS AND FOR THE IMPORTATION OF MEDICINES AND RELATED PRODUCTS

SWOT Analysis Strengths, Weaknesses, Opportunites and Threats (SWOT). SWOT strengths, weaknesses, opportunities, and threats.

Update on China-Denmark Food and Drug Regulatory Cooperation Centre

Appropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products

China Pharmaceutical Equipment Industry Report, Dec. 2011

Incentives and Regulatory Considerations in Orphan Drug/Medical Device Development - Situation in Japan -

Brief Introduction of Aburaihan Company Organization Policy Organization Chart Qualified Human Resource Production Department Engineering Department

APL is a leading Scandinavian contract manufacturer in the Life science sector. turnover och läkemedelsföretag.

Best Logistic and Distribution Solutions For Your Business. Copyright Astra Logistic Ltd.

Jefferies 2015 Global Healthcare Conference June 3, 2015

THE PARTNER FOR INNOVATIVE SOLUTIONS

Road map for the PMDA International Vision April 2013 Pharmaceuticals and Medical Devices Agency, Japan 1

Di Renzo Regulatory Affairs ROME - MILAN - LONDON

BusinessEurope Feedback to the Commission Public Consultation on supplementary Protection Certificates (SPCs) and Patent Research Exemptions

Stephens Fall Investment Conference

CHINA. Australia - China Life Science Summit. . Bio & Pharma Logistics

Transcription:

GEROPHARM NEW PARTNERING OPPORTUNITIES IN SAINT-PETERSBURG PHARMACEUTICAL CLUSTER

USD, billions Russian pharmaceutical market one of the most rapid growing markets in the world 30 25 22 25.5 20 19 16.9 16.1 15 10 5 6.4 8.4 10.8 12.6 0 2004 2005 2006 2007 2008 2009 2010F 2011F 2012F Data source: Pharmexpert market research center 2

Market prognosis In 10 years, the sales volume of pharmaceuticals in Russia will be about $50 billions. This is a very significant number. Actually, we should reach the European level of consumption of pharmaceuticals, which will definitely improve the life expectancy and the quality of life. D.Medvedev, President of Russia 31 august 2009 3

Level of pharmaceutical consumption $700 $450 $350 $127 $350 USA Japan EU 2010 Russia 2020 Russia Data source: IMS-Health, Pharmexpert market research center 4

STRATEGY OF DEVELOPMENT OF RUSSIAN PHARMACEUTICAL INDUSTRY UNTIL 2020 Localization in Russia hi tech pharmaceutical plants Organization of API s manufacturing Conversion to GMP standard Production of currently imported generic and original drugs in Russia PHARMACEUTICAL INDUSTRY DEVELOPMENT VECTOR UP TO 2020 Development of modern research and manufacturing basis according to the international industry standards Manufacturing of generic medicines Manufacturing of innovative medicines Peopleware and infrastructure support of medicines development and manufacturing 5

SAINT-PETERSBURG PHARMACEUTICAL CLUSTER AT GLANCE Characteristics: 18,2 hectare land is ready for construction. Project passed all steps of state expertise Tax-free and Customs-free arrangements Ready to use infrastructure Significant discount on rental arrangements. Possibility of land reacquisition CURRENTLY, THE QUESTION OF PROSPECTIVE BENEFITS FOR LOCAL MANUFACTURERS IS BEING ACTIVELY DISCUSSED Conclusions: Today for foreign pharmaceutical companies to be competitive on the Russian market is strategically important to localize their manufacturing facilities in Russia. Cooperation with Russian pharmaceutical companies is mutually beneficial 6

ADVANTAGES OF PHARMACEUTICAL CLUSTER DEVELOPMENT IN ST PETERSBURG ST PETERSBURG It is one of the regions with the highest rates of economic development in Russia It is one of the world-known scientific centers The city government supports new technological developments High concentration of educational and research institutions in the city The possibility to attract highly qualified scientific and management personnel Tax and customs preferential conditions Example of success : automotive cluster in Saint-Petersburg Toyota GM Nissan Hundai Ford 1 000 000 cars per year 7

PHARMACEUTICAL CLUSTERS AN INTERFACE FOR BUSINESS AND GOVERNMENT COOPERATION The special industrial zone Pushkinskaya has been founded The pharmaceutical cluster concept is approved The state authorities allocated territory for special economical zone Neudorf where R&D facilities will be placed During XIV Petersburg Economical Forum city government and Geropharm company signed an investment agreement on construction of company s pharmaceutical site in the area of pharmaceutical cluster ACHIEVE AIMS IN SHORT TERMS! 8

GEROPHARM TODAY One of the 20 leading Russian pharmaceutical companies a member of the Association of Russian Pharmaceutical Manufacturers from the year 2008 Strong player on Russian and CIS pharmaceutical market during 10 years Innovative drugs developed by Geropharm include Cortexin (neurology), Cortexin for children, Retinalamin (ophtalmology), and recombinant human insulin - Rinsulin Sales are increasing by 38% each year Pharmaceutical R&D center established in special economic zone New GMP-compliant manufacturing plant is being constructed 9

NEW R&D CENTER IN SPECIAL ECONOMIC ZONE «NEUDORF» Implementation of this project allows: Develop final dosage forms for original and generic drugs Synthesize APIs locally and secure quality control for each step of synthesis Create first in Russia GMP-compliant facility for pharmaceutical grade peptide synthesis Develop modern diagnostic systems based on new biomarkers for early diagnostics 10

NEW GEROPHARM FACILITIES IN SAINT-PETERSBURG PHARMACEUTICAL CLUSTER Unique Manufacture Facilities automated production site, fulfill current GMP standards Area under development - 20 000 m 2 6 novel peptide products 6 chemical generics Export to CIS countries Project is a candidate for inclusion into the list of most perspective pharmaceutical projects considering by Ministry of Industry and Commerce of Russian Federation Estimated investment volume 45 millions USD 11

Partnering opportunities R&D partnerships with subsequent registration and marketing of jointly developed products in Russia and CIS countries Manufacturing of jointly developed products on the basis of Geropharm pharmaceutical plant, which intended to be the best modern manufacturing site for sterile injectable products in Russia (in terms of compliance with GMP standards and capacity) Licensing of innovative drugs (after completion of phase II/ III) for Russian territory. Clinical trials. Marketing of the Japanese drugs in Russia using existing Geropharm network. Organization of the joint venture within the boundaries of Saint Petersburg pharmaceutical cluster 12

Thank you for your attention! Tel: +7 (812) 703-79-75 Fax: +7 (812) 703-79-76 Website: www.geropharm.ru Hot Line: 8-800-333-43-76 13